Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Feb 28;12(1):131-134.
doi: 10.21037/hbsn-22-638. Epub 2023 Jan 16.

Redefining resectability in pancreatic cancer after neoadjuvant therapy: are we any closer?

Francis P Robertson  1   2 , Sanjay Pandanaboyana  1   3
Affiliations
Editorial

Redefining resectability in pancreatic cancer after neoadjuvant therapy: are we any closer?

Francis P Robertson et al. Hepatobiliary Surg Nutr. .
No abstract available

Keywords: Pancreatic cancer; neoadjuvant therapy (NAT); resectability.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-22-638/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 2018;18:2-11. 10.1016/j.pan.2017.11.011 - DOI - PubMed
    1. da Costa WL, Jr, Tran Cao HS, Gu X, et al. Bayesian Approach to Understand the Association Between Treatment Down-staging and Survival for Patients With Pancreatic Adenocarcinoma. Ann Surg 2022;275:415-21. 10.1097/SLA.0000000000005249 - DOI - PubMed
    1. Oba A, Del Chiaro M, Satoi S, et al. New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). J Hepatobiliary Pancreat Sci 2022;29:725-31. 10.1002/jhbp.1049 - DOI - PubMed
    1. Ghaneh P, Palmer D, Cicconi S, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2023;8:157-68. 10.1016/S2468-1253(22)00348-X - DOI - PubMed
    1. van Veldhuisen E, Klompmaker S, Janssen QP, et al. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Ann Surg Oncol 2023;30:1463-73. .10.1245/s10434-022-12387-2 - DOI - PMC - PubMed